tiprankstipranks
4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
PremiumPress Releases4DMT Announces Update on Regulatory Interactions and Development Path for 4D-710 for Treatment of Cystic Fibrosis
22d ago
4DMT to Participate in Upcoming Investor Conferences
PremiumPress Releases
4DMT to Participate in Upcoming Investor Conferences
2M ago
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
PremiumPress Releases
4DMT Reports Full Year 2023 Financial Results and Operational Highlights
2M ago
4D Molecular reinstated with a Buy at Goldman Sachs
PremiumThe Fly4D Molecular reinstated with a Buy at Goldman Sachs
2M ago
4D Molecular 6.59M share Secondary priced at $29.50
PremiumThe Fly
4D Molecular 6.59M share Secondary priced at $29.50
2M ago
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
PremiumPress Releases
4D Molecular Therapeutics Announces Pricing of Upsized Public Offering of Common Stock
2M ago
4D Molecular price target raised to $70 from $50 at BMO Capital
PremiumThe Fly4D Molecular price target raised to $70 from $50 at BMO Capital
2M ago
4D Molecular cystic fibrosis treatment granted FDA orphan designation
PremiumThe Fly
4D Molecular cystic fibrosis treatment granted FDA orphan designation
2M ago
4D Molecular price target raised to $35 from $25 at RBC Capital
PremiumThe Fly
4D Molecular price target raised to $35 from $25 at RBC Capital
2M ago

Trending

Name
Price
Price Change
S&P 500
Dow Jones
Nasdaq 100